Kim Kangpyo, Lee Joongyo, Seong Jinsil
Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea.
J Hepatocell Carcinoma. 2022 Apr 29;9:357-366. doi: 10.2147/JHC.S361045. eCollection 2022.
Skull base metastasis (SBM) from hepatocellular carcinoma (HCC) presents detrimental survival outcomes with cranial nerve symptoms; however, they have received little attention. This study aimed to investigate the clinical presentation and efficacy of radiation therapy (RT) in patients with SBM from HCC.
We identified patients with SBM from HCC in Yonsei Cancer Center from 2005 to 2019. Image evaluations and SBM-related symptoms were reviewed. Overall survival was calculated using the Kaplan-Meier method and compared through the Log rank test. The oligometastasis group included patients with less than five foci of tumors, while the extensive metastasis group presented five or more sites.
The incidence of SBM from HCC was 1.5% (58/3793 patients), commonly found in the middle cranial fossa. SBM associated symptoms presented in 51 patients, and the most common were head and neck area pain, and orbital symptoms, The palliation rate after RT was 65% (24/39 patients) for overall symptoms and 83.3% (20/24 patients) for cranial nerve symptoms. In whole cohort, overall survival was analyzed, and the median overall survival of patients with oligometastasis was better than extensive metastasis (23.7 months vs 1.8 months, p < 0.001). In subgroup who received RT (39 patients), the median overall survival was 23.7 and 2.7 months for patients with oligo and extensive metastasis, respectively (p < 0.001).
This study confirmed clinical features of SBM from HCC. Overall survival was generally poor, but patients presenting oligometastasis seemed to have possibility of relative long-term survival. Although radiation was effective in SBM-induced symptom relief, dose-response relationship in local control rate and overall survival needs further studies with larger number of patients.
肝细胞癌(HCC)的颅底转移(SBM)会导致不良的生存结果并伴有颅神经症状;然而,它们很少受到关注。本研究旨在调查HCC患者发生SBM时的临床表现及放射治疗(RT)的疗效。
我们确定了2005年至2019年在延世癌症中心患有HCC并发生SBM的患者。回顾了图像评估和与SBM相关的症状。采用Kaplan-Meier方法计算总生存期,并通过对数秩检验进行比较。寡转移组包括肿瘤病灶少于5个的患者,而广泛转移组有5个或更多转移部位。
HCC发生SBM的发生率为1.5%(58/3793例患者),常见于中颅窝。51例患者出现SBM相关症状,最常见的是头颈部疼痛和眼眶症状。RT后总体症状的缓解率为65%(24/39例患者),颅神经症状的缓解率为83.3%(20/24例患者)。在整个队列中分析了总生存期,寡转移患者的中位总生存期优于广泛转移患者(23.7个月对1.8个月,p<0.001)。在接受RT的亚组(39例患者)中,寡转移和广泛转移患者的中位总生存期分别为23.7个月和2.7个月(p<0.001)。
本研究证实了HCC患者发生SBM的临床特征。总体生存期通常较差,但出现寡转移的患者似乎有相对长期生存的可能性。尽管放射治疗对缓解SBM引起的症状有效,但局部控制率和总生存期的剂量反应关系需要更多患者的进一步研究。